The incidence of cardiovascular events after hospitalization due to CAP and their association with different inflammatory markers

BMC Pulmonary Medicine

Javier Aspa⁵  Julio Ancochea⁵  Carmen Suárez⁷  Hortensia de la Fuente⁴  Ana Díaz López¹  Sergio Luquero Bueno³  Belén Arnalich²  Francisco Rodríguez Salvanes⁸  Lorena Vega Piris⁸  Guillermo Fernández Jiménez⁶  José Curbelo³  José María Galván Román⁷  Mara Ortega-Gómez³  Olga Rajas⁵ 

[1] Servicio de Análisis Clínicos, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Hospital, Universitario de la Princesa, IP, Madrid, España;Servicio de Neumología, Hospital Universitario del Henares, Madrid, España;Biobanco Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, IP, Madrid, España;Servicio de Inmunología, Hospital Universitario de La Princesa, Madrid, España;Servicio de Neumología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, IP, Madrid, España;Unidad de información Clínica, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, IP, Madrid, España;Servicio de Medicina Interna, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, IP, Madrid, España;Unidad Metodológica. Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, IP, Madrid, España

关键词: CAP late mortality;    Inflammatory markers;    Cardiovascular events;    Community-acquired pneumonia (CAP);   

Others  :  1090885
DOI  :  10.1186/1471-2466-14-197

 received in 2014-11-13, accepted in 2014-12-04,  发布年份 2014

【 摘 要 】

Background

Late prognosis of Community-Acquired Pneumonia (CAP) patients is related to cardiovascular events. Persistence of inflammation-related markers, defined by high circulatory levels of interleukin 6 and 10 (IL-6/IL-10), is associated with a higher post-event mortality rate for CAP patients. However, association between these markers and other components of the immune response, and the risk of cardiovascular events, has not been adequately explored. The main objectives of this study are: 1) to quantify the incidence of cardiovascular disease, in the year post-dating their hospital admittance due to CAP and, 2) to describe the distribution patterns of a wide spectrum of inflammatory markers upon admittance to and release from hospital, and to determine their relationship with the incidence of cardiovascular disease.

Methods/design

A cohort prospective study. All patients diagnosed and hospitalized with CAP will be candidates for inclusion. The study will take place in the Universitary Hospital La Princesa, Spain, during two years. Two samples of blood will be taken from each patient: the first upon admittance and the second one prior to release, in order to analyse various immune agents. The main determinants are: pro-adrenomedullin, copeptin, IL-1, IL-6, TNF-α, IL-17, IFN-γ, IL-10 and TGF-β, E-Selectin, ICAM-1, VCAM-1 and subpopulations of peripheral T lymphocytes (T regulator, Th1 and Th17), together with other clinical and analytical variables. Follow up will start at admittance and finish a year after discharge, registering incidence of death and cardiovascular events. The main objective is to establish the predictive power of different inflammatory markers in the prognosis of CAP, in the short and long term, and their relationship with cardiovascular disease.

Discussion

The level of some inflammatory markers (IL-6/IL-10) has been proposed as a means to differentiate the degree of severity of CAP, but their association with cardiovascular risk is not well established. In this study we aim to define new inflammatory markers associated with cardiovascular disease that could be helpful for the prognosis of CAP patients, by describing the distribution of a wide spectrum of inflammatory mediators and analyzing their association with the incidence of cardiovascular disease and mortality one year after release from hospital.

【 授权许可】

   
2014 Rajas et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: The top 10 causes of death. Geneva: World Health Organization; 2013. Available from http://www.who.int/mediacentre/factsheets/fs310/en/index.html webcite
• [2]Welte T, Torres A, Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012, 67:71-79.
• [3]Wunderink RG, Waterer GW: Clinical practice. Community-acquired pneumonia. N Engl J Med 2014, 370(6):543-551.
• [4]Brancati FL, Chow JW, Wagener MM, Vacarello SJ, Yu VL: Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet 1993, 342(8862):30-33.
• [5]Waterer GW, Kessler LA, Wunderink RG: Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 169(8):910-914.
• [6]Yende S, Angus DC, Ali IS, Somes G, Newman AB, Bauer D, Garcia M, Harris TB, Kritchevsky SB: Influence of comorbid conditions on long-term mortality after pneumonia in older people. J Am Geriatr Soc 2007, 55(4):518-525.
• [7]Bordon J, Wiemken T, Peyrani P, Paz ML, Gnoni M, Cabral P, Venero Mdel C, Ramirez J: Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010, 138(2):279-283.
• [8]Johnstone J, Eurich DT, Majumdar SR, Jin Y, Marrie TJ: Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008, 87(6):329-334.
• [9]Adamuz J, Viasus D, Jimenez-Martinez E, Isla P, Garcia-Vidal C, Dorca J, Carratalà J: Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J Infect 2014, 68:534-541.
• [10]Kruger S, Frechen D: Cardiovascular complications and comorbidities in CAP. In European Respiratory monograph. Edited by Chalmers JD, Pletz MW, Aliberti S. Sheffield: Europen Respiratory Society; 2014:256-265.
• [11]Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S, Cameron DW, Fergusson DA: Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011, 8(6):e1001048.
• [12]Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ: Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012, 125(6):773-781.
• [13]Peyrani P, Ramirez J: What is the association of cardiovascular events with clinical failure in patients with community-acquired pneumonia? Infect Dis Clin North Am 2013, 27(1):205-210.
• [14]Perry TW, Pugh MJ, Waterer GW, Nakashima B, Orihuela CJ, Copeland LA, Restrepo MI, Anzueto A, Mortensen EM: Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med 2011, 124(3):244-251.
• [15]Musher DM, Rueda AM, Kaka AS, Mapara SM: The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007, 45(2):158-165.
• [16]Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, Moffett B, Gordon J, Blasi F, Bordon J: Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008, 47(2):182-187.
• [17]Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ: Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008, 46(4):550-556.
• [18]Corrales-Medina VF, Serpa J, Rueda AM, Giordano TP, Bozkurt B, Madjid M, Tweardy D, Musher DM: Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009, 88(3):154-159.
• [19]Milbrandt EB, Reade MC, Lee M, Shook SL, Angus DC, Kong L, Carter M, Yealy DM, Kellum JA: Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009, 15(11–12):438-445.
• [20]Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells 3rd SW: Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J 2007, 28(10):1205-1210.
• [21]Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351(25):2611-2618.
• [22]Stoll G, Bendszus M: Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006, 37(7):1923-1932.
• [23]Soto-Gomez N, Anzueto A, Waterer GW, Restrepo MI, Mortensen EM: Pneumonia: an arrhythmogenic disease? Am J Med 2013, 126(1):43-48.
• [24]Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Müller B: Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia[ISRCTN04176397]. Crit Care 2006, 10(3):R96. BioMed Central Full Text
• [25]Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T: Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010, 182(11):1426-1434.
• [26]Kruger S, Welte T: Biomarkers in community-acquired pneumonia. Expert Rev Respir Med 2012, 6(2):203-214.
• [27]Schuetz P, Litke A, Albrich WC, Mueller B: Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013, 26(2):159-167.
• [28]Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E, de Pablo F, Ferrer M, Menendez R, Torres A: Prognostic power of proadrenomedullin in community-acquired peumonia is independent on etiology. Eur Respir J 2012, 39(5):1144-1155.
• [29]Martinez R, Menendez R, Reyes S, Polverino E, Cilloniz C, Martinez A, Esquinas C, Filella X, Ramírez P, Torres A: Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J 2011, 37(2):393-399.
• [30]Yende S, D'Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, Kong L, Carter M, Angus DC: Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177(11):1242-1247.
• [31]Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101(15):1767-1772.
• [32]Paats MS, Bergen IM, Hanselaar WE, van Zoelen EC, Verbrugh HA, Hoogsteden HC, van den Blink B, Hendriks RW, van der Eerden MM: T helper 17 cells are involved in the local and systemic inflammatory response in community-acquired pneumonia. Thorax 2014, 68(5):468-474.
• [33]Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, Khader SA, Dubin PJ, Enelow RI, Kolls JK, Alcorn JF: Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011, 186(3):1666-1674.
• [34]Kolls JK, Khader SA: The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 2010, 21(6):443-448.
• [35]Korn T, Oukka M, Kuchroo V, Bettelli E: Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007, 19(6):362-371.
• [36]Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99-146.
• [37]Shevach EM: Biological functions of regulatory T cells. Adv Immunol 2011, 112:137-176.
• [38]Ley K, Laudanna C, Cybulsky MI, Nourshargh S: Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007, 7(9):678-689.
• [39]Demerath E, Towne B, Blangero J, Siervogel RM: The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001, 28(6):664-678.
• [40]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
• [41]De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines: European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardio Prev Rev 2003, 10(Suppl 1):S1-S78.
• [42]Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377-382.
• [43]Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250.
• [44]Corrales-Medina VF, Taljaard M, Fine MJ, Dwivedi G, Perry JJ, Musher DM, Chirinos JA: Risk stratification for cardiac complications in patients hospitalized for community-acquired pneumonia. Mayo Clin Proc 2014, 89(1):60-68.
• [45]Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratala J: Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013, 66(1):27-33.
• [46]Torres A, Ramirez P, Montull B, Menendez R: Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012, 33(3):266-271.
• [47]Kruger S, Welte T, Ewig S: Another view on the prediction of outcomes in patients with community-acquired pneumonia. Eur Respir J 2011, 38(4):991-992. author reply 992–3
• [48]Ewig S, Torres A: Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J 2011, 38(2):253-260.
• [49]Fernandez-Botran R, Uriarte SM, Arnold FW, Rodriguez-Hernandez L, Rane MJ, Peyrani P, Wiemken T, Kelley R, Uppatla S, Cavallazzi R, Blasi F, Morlacchi L, Aliberti S, Jonsson C, Ramirez JA, Bordon J: Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia. Inflammation 2014, 2014:2014.
• [50]Paats MS, Bergen IM, Hanselaar WE, van Groeninx Zoelen EC, Hoogsteden HC, Hendriks RW, van der Eerden MM: Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. Eur Respir J 2013, 41(6):1378-1385.
• [51]Ramirez P, Ferrer M, Marti V, Reyes S, Martinez R, Menendez R, Ewig S, Torres A: Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med 2011, 39(10):2211-2217.
• [52]Craig A, Mai J, Cai S, Jeyaseelan S: Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun 2009, 77(2):568-575.
• [53]Bordon J, Aliberti S, Fernandez-Botran R, Uriarte SM, Rane MJ, Duvvuri P, Peyrani P, Morlacchi LC, Blasi F, Ramirez JA: Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013, 17(2):e76-e83.
• [54]Menendez R, Sahuquillo-Arce JM, Reyes S, Martinez R, Polverino E, Cilloniz C, Cilloniz C, Cordoba JG, Montull B, Torres A: Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012, 141(6):1537-1545.
• [55]Calbo E, Garau J: Of mice and men: innate immunity in pneumococcal pneumonia. Int J Antimicrob Agents 2010, 35(2):107-113.
• [56]Kruger S, Ewig S, Kunde J, Hartmann O, Marre R, Suttorp N, Welte T: Assessment of inflammatory markers in patients with community-acquired pneumonia–influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010, 411(23–24):1929-1934.
• [57]Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC: Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007, 167(15):1655-1663.
• [58]Remick DG, Bolgos G, Copeland S, Siddiqui J: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005, 73(5):2751-2757.
• [59]Yende S, Tuomanen EI, Wunderink R, Kanaya A, Newman AB, Harris T, de Rekeneire N, Kritchevsky SB: Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med 2005, 172(11):1440-1446.
• [60]El Solh A, Pineda L, Bouquin P, Mankowski C: Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr 2006, 6:12. BioMed Central Full Text
• [61]Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ: Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002, 162(9):1059-1064.
• [62]Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, Malats N, Briggs A, Schroter S, Altman DG, Hemingway H: Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 2013, 10(2):e1001380.